Cipla (CIPLA) Q1 26/27 earnings summary

Executive summary

• Achieved highest-ever Q1 consolidated revenue of INR 7,119.28 Cr, up year-over-year, with strong growth in India and steady global performance.

• Unaudited standalone and consolidated financial results for the quarter ended 30th June 2026 were approved and released.

• EBITDA stood at INR 1,192 Cr with a margin of 16.7%, while PAT was INR 789 Cr, reflecting margin compression compared to last year.

• Launched several new products in India and North America, including the first AB-rated gVentolin in the US.

Financial highlights

• Consolidated revenue from operations for Q1 FY27 was INR 7,119.28 Cr, up from INR 6,541.20 Cr in Q1 FY26 and INR 6,957.47 Cr in Q4 FY26.

• EBITDA declined to INR 1,192 Cr from INR 1,778 Cr, with margin dropping to 16.7% from 25.6%.

• PAT decreased to INR 789 Cr from INR 1,298 Cr, with PAT margin at 11.1% versus 18.7% last year.

• Basic and diluted EPS (consolidated) for the quarter were INR 9.77 and INR 9.76, respectively.

• R&D spend was INR 486 Cr, representing 6.8% of revenue.

Outlook and guidance

• Plans to ramp up supply of new launches in North America and continue portfolio expansion in India.

• Ongoing focus on ESG goals, including renewable energy and water neutrality targets for manufacturing.

• The company continues to expect a favorable outcome in ongoing regulatory litigations and has not made provisions for certain demand notices.